-DOCSTART- -X- O
Decitabine -X- _ O
has -X- _ O
been -X- _ O
explored -X- _ O
as -X- _ O
a -X- _ O
reduced‐intensity -X- _ O
therapy -X- _ O
for -X- _ O
older -X- _ O
or -X- _ O
unfit -X- _ O
patients -X- _ O
with -X- _ O
acute -X- _ O
myeloid -X- _ O
leukemia -X- _ O
( -X- _ O
AML -X- _ O
) -X- _ O
. -X- _ O
To -X- _ O
better -X- _ O
understand -X- _ O
the -X- _ O
risk -X- _ O
of -X- _ O
infections -X- _ O
during -X- _ O
decitabine -X- _ O
treatment -X- _ O
, -X- _ O
we -X- _ O
retrospectively -X- _ O
examined -X- _ O
the -X- _ O
culture -X- _ O
results -X- _ O
from -X- _ O
each -X- _ O
infection‐related -X- _ O
serious -X- _ O
adverse -X- _ O
event -X- _ O
that -X- _ O
occurred -X- _ O
among -X- _ O
85 -X- _ B-Patient
AML -X- _ I-Patient
and -X- _ I-Patient
myelodysplastic -X- _ I-Patient
syndromes -X- _ I-Patient
( -X- _ I-Patient
MDS -X- _ I-Patient
) -X- _ I-Patient
patients -X- _ I-Patient
treated -X- _ O
in -X- _ O
a -X- _ O
prospective -X- _ O
clinical -X- _ O
study -X- _ O
using -X- _ O
10‐day -X- _ B-Intervention
cycles -X- _ I-Intervention
of -X- _ I-Intervention
decitabine -X- _ I-Intervention
at -X- _ O
Washington -X- _ O
University -X- _ O
School -X- _ O
of -X- _ O
Medicine. -X- _ O
Culture -X- _ O
results -X- _ O
were -X- _ O
available -X- _ O
for -X- _ O
163 -X- _ O
infection‐related -X- _ O
complications -X- _ O
that -X- _ O
occurred -X- _ O
in -X- _ O
70 -X- _ O
patients -X- _ O
: -X- _ O
90 -X- _ O
( -X- _ O
55.2 -X- _ O
% -X- _ O
) -X- _ O
events -X- _ O
were -X- _ O
culture‐negative -X- _ O
, -X- _ O
32 -X- _ O
( -X- _ O
19.6 -X- _ O
% -X- _ O
) -X- _ O
were -X- _ O
gram‐positive -X- _ O
bacteria -X- _ O
, -X- _ O
20 -X- _ O
( -X- _ O
12.3 -X- _ O
% -X- _ O
) -X- _ O
were -X- _ O
gram‐negative -X- _ O
bacteria -X- _ O
, -X- _ O
12 -X- _ O
( -X- _ O
7.4 -X- _ O
% -X- _ O
) -X- _ O
were -X- _ O
mixed -X- _ O
, -X- _ O
6 -X- _ O
( -X- _ O
3.7 -X- _ O
% -X- _ O
) -X- _ O
were -X- _ O
viral -X- _ O
, -X- _ O
2 -X- _ O
( -X- _ O
1.2 -X- _ O
% -X- _ O
) -X- _ O
were -X- _ O
fungal -X- _ O
, -X- _ O
and -X- _ O
1 -X- _ O
( -X- _ O
0.6 -X- _ O
% -X- _ O
) -X- _ O
was -X- _ O
mycobacterial. -X- _ O
Infection‐related -X- _ O
mortality -X- _ O
occurred -X- _ O
in -X- _ O
3 -X- _ O
/ -X- _ O
24 -X- _ O
( -X- _ O
13 -X- _ O
% -X- _ O
) -X- _ O
of -X- _ O
gram‐negative -X- _ O
events -X- _ O
, -X- _ O
and -X- _ O
0 -X- _ O
/ -X- _ O
51 -X- _ O
gram‐positive -X- _ O
events. -X- _ O
On -X- _ O
average -X- _ O
, -X- _ O
nearly -X- _ O
one -X- _ O
third -X- _ O
of -X- _ O
patients -X- _ O
experienced -X- _ O
an -X- _ O
infection‐related -X- _ O
complication -X- _ O
with -X- _ O
each -X- _ O
cycle -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
incidence -X- _ O
did -X- _ O
not -X- _ O
decrease -X- _ O
during -X- _ O
later -X- _ O
cycles. -X- _ O
In -X- _ O
summary -X- _ O
, -X- _ O
in -X- _ O
patients -X- _ O
receiving -X- _ O
10‐day -X- _ B-Intervention
decitabine -X- _ I-Intervention
, -X- _ O
infectious -X- _ B-Outcome
complications -X- _ I-Outcome
are -X- _ I-Outcome
common -X- _ I-Outcome
and -X- _ I-Outcome
may -X- _ I-Outcome
occur -X- _ I-Outcome
during -X- _ I-Outcome
any -X- _ I-Outcome
cycle -X- _ I-Outcome
of -X- _ I-Outcome
therapy. -X- _ I-Outcome
Although -X- _ O
febrile -X- _ B-Outcome
events -X- _ I-Outcome
are -X- _ I-Outcome
commonly -X- _ I-Outcome
culture‐negative -X- _ I-Outcome
, -X- _ O
gram‐positive -X- _ B-Outcome
infections -X- _ I-Outcome
are -X- _ I-Outcome
the -X- _ I-Outcome
most -X- _ I-Outcome
frequent -X- _ I-Outcome
source -X- _ I-Outcome
of -X- _ I-Outcome
culture‐positive -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ O
but -X- _ O
gram‐negative -X- _ B-Outcome
infections -X- _ I-Outcome
represent -X- _ I-Outcome
a -X- _ I-Outcome
significant -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
mortality -X- _ I-Outcome
in -X- _ I-Outcome
AML -X- _ I-Outcome
and -X- _ I-Outcome
MDS -X- _ I-Outcome
patients -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
decitabine -X- _ I-Outcome
. -X- _ O

